Zura Bio

ZURANasdaq Cayman Islands Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$566.661 M

$5.97 +4.47%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$68.7M

Loss-making

Shares outstanding

94,880,710

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#59Allogene TherapeuticsALLO$693.8M
#60Tectonic TherapeuticTECX$584.6M
#61Zura BioZURA$566.7M
#624D Molecular TherapeuticsFDMT$562.0M
#63Autolus TherapeuticsAUTL$561.6M

Where these numbers come from

Share counts and financials for Zura Bio are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.